Remepy enables pharma companies to launch software-drug combinations. Each of our apps is tailored to specific clinical indications and drug mechanisms of action, increasing the drug’s efficacy. Engagement with our apps activates brain mechanisms with downstream impact on the immune system as well as direct improvement of synaptic connectivity and neuroplasticity.
The core of Remepy’s apps is the Digital MoleculeTM. This is a unique digital intervention protocol created by Remepy’s scientists, tailored for each clinical indication, specific drug mechanism, drug treatment protocol and patient journey. The Digital MoleculeTM has a synergistic effect on a molecular level with each drug, increasing its efficacy, as well addressing specific co-morbidities and side effects. Our initial Digital MoleculesTM focus on immune system modulation as well as on synaptic connectivity and neuro-plasticity.
Our apps include several additional key modules:
Remepy interventions have a two-pronged approach to improving patient outcomes. These precise interventions, together with drug molecules creates a new mechanism of action, in the form of a software-drug combination.
Psychological and cognitive interventions can restore neuro-endocrine and neuro-immunological balance by influencing hormones such as cortisol and adrenaline as well as cytokines such as IL-6 and INFγ.
This immunological rebalancing creates better conditions for improved pharmacokinetics and pharmacodynamics, directly enhancing efficacy and safety profiles of drugs.
Our evidence-based psychological interventions are also used to directly reduce comorbidities and medication side effects such as depression, anxiety, fatigue, and pain. This can have an overall improvement in patients' quality of life.
By reprogramming the adult brain, Remepy’s interventions can increase synaptic connectivity and influence brain areas that enhance patients’ ability to self-regulate and deal with negative emotions and pain.
Increased brain connectivity can help prevent excessive stress-related activation of the hypothalamic-pituitary axis, further rebalancing the immune system.
By rewiring the brain and balancing the immune system, our interventions foster optimal conditions for enhanced drug effect and improved disease outcomes in many neurodegenerative diseases, such as Alzheimer’s disease.
Remepy’s vision has been to enhance medicine by digitally invoking natural processes in our body.
There is a tremendous opportunity to rewrite the drug development process by harnessing the power of our digital world.
We have assembled a unique multidisciplinary team of software engineers, scientists, immunologists, physicians, psychologists, drug developers, computer scientists, and entrepreneurs to form a new kind of company, made possible by advances in technology, patient data and improved understanding of natural immune processes.
Head of Brain Cognition & Tech,
RU Institution, Harvard & HUJI
Chief Medical Officer & President of US Operations, Quark Pharmaceuticals